Akili, Inc. (NASDAQ:AKLI) Sees Significant Growth in Short Interest

Akili, Inc. (NASDAQ:AKLI) saw a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 623,800 shares, a growth of 27.9% from the May 15th total of 487,700 shares. Currently, 1.6% of the company’s shares are sold short. Based on an average trading volume of 1,850,000 shares, the days-to-cover ratio is currently 0.3 days.

Akili Price Performance

Shares of AKLI stock opened at $0.42 on Monday. Akili has a twelve month low of $0.19 and a twelve month high of $1.40. The stock has a market capitalization of $33.26 million, a price-to-earnings ratio of -0.69 and a beta of 1.71. The stock has a fifty day simple moving average of $0.36 and a two-hundred day simple moving average of $0.35. The company has a current ratio of 5.80, a quick ratio of 5.80 and a debt-to-equity ratio of 0.08.

Akili (NASDAQ:AKLI) last issued its earnings results on Tuesday, May 14th. The company reported ($0.13) earnings per share for the quarter. Akili had a negative return on equity of 79.93% and a negative net margin of 2,492.04%. The firm had revenue of $0.38 million during the quarter. On average, analysts predict that Akili will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Akili

A hedge fund recently raised its stake in Akili stock. Longitude Cayman Ltd. grew its position in Akili, Inc. (NASDAQ:AKLI) by 75.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 350,000 shares of the company’s stock after buying an additional 150,000 shares during the quarter. Longitude Cayman Ltd. owned 0.45% of Akili worth $102,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 53.12% of the company’s stock.

About Akili

Akili, Inc, a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.